drugset
Drugs / Ivonescimab
last change 8 days ago re-read 8 days ago

Ivonescimab

also known as AK112 · SMT112 · Envafolimab · Ivonescimab Injection · ivosidan · Ivosimab

Monoclonal antibody

Developed for
non-small cell lung carcinoma · small cell lung carcinoma · colorectal cancer · cancer · hepatocellular carcinoma · triple-negative breast carcinoma · head and neck squamous cell carcinoma · malignant pancreatic neoplasm
+59 more · biliary tract cancer · esophageal squamous cell carcinoma · female breast carcinoma · gastric cancer · breast cancer · nasopharyngeal carcinoma · cervical cancer · clear cell renal carcinoma · colorectal adenocarcinoma · hormone receptor-positive breast cancer · metastasis from malignant tumor of colon · metastatic malignant neoplasm in the brain · neoplastic meningitis · pancreatic ductal adenocarcinoma · rectal cancer · soft tissue sarcoma · squamous cell lung carcinoma · urothelial carcinoma · adrenal cortex carcinoma · bone sarcoma · carcinoma · cervical carcinoma · colon carcinoma · endometrial cancer · endometrium neoplasm · esophageal adenocarcinoma · esophageal cancer · female reproductive organ cancer · gastric adenocarcinoma · gastroesophageal adenocarcinoma · glioblastoma · Her2-receptor negative breast cancer · invasive lobular breast carcinoma · leiomyosarcoma · lung neoplasm · malignant pleural mesothelioma · metastatic malignant neoplasm · metastatic melanoma · metastatic neoplasm · mucosal melanoma · multiple polyglandular tumor · neuroendocrine neoplasm · non-small cell squamous lung carcinoma · ovarian cancer · ovarian carcinoma · ovarian neoplasm · paraganglioma · pheochromocytoma · pleural mesothelioma · renal cell carcinoma · respiratory system cancer · salivary gland adenoid cystic carcinoma · salivary gland carcinoma · skin angiosarcoma · skin squamous cell carcinoma · thymic carcinoma · thymus cancer · urinary bladder carcinoma · uterine cervix neoplasm
Investigated by
Akeso · Summit Therapeutics · Sun Yat-sen University · Fudan University · M.D. Anderson Cancer Center · Memorial Sloan Kettering Cancer Center
+77 more · Tianjin Medical University Cancer Institute and Hospital · Akesobio · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · National Cancer Institute (NCI) · Peking University Cancer Hospital & Institute · Sichuan University · UNICANCER · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Akeso Biopharma Co., Ltd. · Akeso Biopharma, Inc. · City of Hope Medical Center · Innovent Biologics, Inc. · Massachusetts General Hospital · Shandong Cancer Hospital and Institute · The First Affiliated Hospital of Zhengzhou University · West China Hospital · Zhejiang Cancer Hospital · Anhui Provincial Hospital · Belgian Group of Digestive Oncology · Cancer Research UK & UCL Cancer Trials Centre · Cedars-Sinai Medical Center · French Cooperative Thoracic Intergroup · Fujian Cancer Hospital · GlaxoSmithKline · Glenn J. Hanna · Groupe Oncologie Radiotherapie Tete et Cou · Guangdong Association of Clinical Trials · Guangdong Provincial People's Hospital · Guangzhou Medical University · Haitao Zhao, MD · Harbin Medical University · Henan Cancer Hospital · Huai'an First People's Hospital · Hubei Cancer Hospital · Hunan Province Tumor Hospital · Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Jiangsu Cancer Institute & Hospital · Jiangsu Province Nanjing Brain Hospital · Jonsson Comprehensive Cancer Center · Lei Liu · MediLink Therapeutics (Suzhou) Co., Ltd. · Ming-Yuan Chen · Multitude Therapeutics Inc. · Nanjing Shihejiyin Technology, Inc. · National University Hospital, Singapore · Obstetrics & Gynecology Hospital of Fudan University · Peking Union Medical College · Peking Union Medical College Hospital · Peking University Hospital of Stomatology · PrECOG, LLC. · QuantumLeap Healthcare Collaborative · Revolution Medicines, Inc. · SWOG Cancer Research Network · Second Affiliated Hospital, Zhejiang University, School of Medicine · Second Xiangya Hospital of Central South University · Shanghai Allink Biotherapeutics Co., Ltd. · Shanghai Chest Hospital · Shanghai Pulmonary Hospital, Shanghai, China · Shanghai Yizhong Pharmaceutical Co., Ltd. · Shanxi Province Cancer Hospital · Shaodong Hong · Sheng Zhang · Shengjing Hospital · Shuangyue Liu · Strategic Alliance · Swiss Cancer Institute · Tang-Du Hospital · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · The First Hospital of Jilin University · The Second Affiliated Hospital of Dalian Medical University · Three Gorges Hospital of Chongqing University · TransThera Sciences (Nanjing), Inc. · University of Michigan Rogel Cancer Center · Virogin Biotech Ltd. · all 83 on the full record

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Filed China (NMPA) — non-small cell lung carcinoma 2024-07-29

“依沃西一线治疗PD-L1表达阳性NSCLC的新药上市申请（sNDA）也已获CDE受理” akesobio.com ↗

“7月29日，依沃西该项适应症的新药上市申请（sNDA）获得了CDE的受理.” akesobio.com ↗
Filed China (NMPA) — non-small cell lung carcinoma 2023-08-18

“值得关注的是，AK112除了有1项适应症的上市申请在国内被CDE受理” akesobio.com ↗

“依沃西已经有1项新药上市申请获得中国国家药品监督管理局受理并优先审评” akesobio.com ↗

“目前依沃西在国内已经有1项新药上市申请获得国家药品监督管理局受理” akesobio.com ↗

“2023年8月，依沃西新药上市申请获得国家药品监督管理局受理” akesobio.com ↗

“目前依沃西一项适应症的上市申请（NDA）已被CDE受理” akesobio.com ↗

“依沃西除了1项新药上市申请成功获得NMPA受理” akesobio.com ↗

“AK112-301研究：NDA已被CDE受理” akesobio.com ↗

Trials 163 · started per year

today
1
1
1
5
9
9
24
67
45
1
2010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 110 trials
Phase 1 NCT07363408 Dec 2026 → Jul 2027 expected colorectal carcinoma City of Hope Medical Center Not yet recruiting No outcome recorded
Phase 1 NCT07650825 Aug 2026 → Jan 2027 expected cancer Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 1 NCT07619339 May 2026 → May 2029 expected non-small cell lung carcinoma Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Phase 1 NCT07340476 Dec 2025 → Apr 2026 overdue — Akeso Active not recruiting No outcome recorded
Phase 1 NCT06913218 Jul 2025 → Feb 2028 expected pancreatic ductal adenocarcinoma Akeso Not yet recruiting No outcome recorded
Phase 1 NCT06990620 Jun 2025 → Jun 2027 expected hepatocellular carcinoma Fudan University Not yet recruiting No outcome recorded
Phase 1 NCT06868732 Apr 2025 → Jun 2028 expected non-small cell lung carcinoma Jiangsu Alphamab Biopharmaceuticals Co., Ltd Recruiting No outcome recorded
Phase 1 NCT06424626 May 2024 → Dec 2027 expected metastatic melanoma, mucosal melanoma Peking University Cancer Hospital & Institute Enrolling by invitation No outcome recorded
Phase 1 NCT05116007 Mar 2021 → Dec 2023 small cell lung carcinoma Akeso Completed No outcome recorded
Phase 1 NCT04047290 Sep 2019 → Feb 2024 cancer Akeso Biopharma, Inc. Completed No outcome recorded
Phase 1/231 trials
Phase 1/2 NCT07602855 Sep 2026 → Jun 2029 expected lung neoplasm GlaxoSmithKline Recruiting No outcome recorded
Phase 1/2 NCT07590531 Jun 2026 → May 2027 expected non-small cell lung carcinoma Multitude Therapeutics Inc. Recruiting No outcome recorded
Phase 1/2 NCT07623356 Jun 2026 → Jun 2028 expected non-small cell lung carcinoma Akeso Not yet recruiting No outcome recorded
Phase 1/2 NCT07560124 Jun 2026 → Jun 2028 expected breast cancer Akeso Not yet recruiting No outcome recorded
Phase 1/2 NCT07594522 May 2026 → May 2028 expected non-small cell lung carcinoma Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Phase 1/2 NCT07535463 Apr 2026 → Apr 2028 expected non-small cell lung carcinoma Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Phase 1/2 NCT07535437 Apr 2026 → Apr 2028 expected non-small cell lung carcinoma Memorial Sloan Kettering Cancer Center Recruiting No outcome recorded
Phase 1/2 NCT07357220 Mar 2026 → Feb 2027 expected metastasis from malignant tumor of colon Akeso Not yet recruiting No outcome recorded
Phase 1/2 NCT07339839 Mar 2026 → Sep 2027 expected non-small cell lung carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 1/2 NCT07397338 Jan 2026 → May 2029 expected colorectal cancer, metastatic neoplasm, non-small cell lung carcinoma Revolution Medicines, Inc. Recruiting No outcome recorded
Phase 2103 trials
Phase 2 NCT07743138 Feb 2027 → May 2028 expected adrenal cortex carcinoma, paraganglioma, pheochromocytoma M.D. Anderson Cancer Center Not yet recruiting No outcome recorded
Phase 2 NCT07655570 Nov 2026 → May 2027 expected skin angiosarcoma M.D. Anderson Cancer Center Not yet recruiting No outcome recorded
Phase 2 NCT07819591 Oct 2026 → Dec 2028 expected small cell lung carcinoma Shaodong Hong Not yet recruiting No outcome recorded
Phase 2 NCT07854600 Oct 2026 → Oct 2028 expected biliary tract cancer Haitao Zhao, MD Recruiting No outcome recorded
Phase 2 NCT07359456 Aug 2026 → Aug 2029 expected colorectal cancer UNICANCER Not yet recruiting No outcome recorded
Phase 2 NCT07809893 Aug 2026 → Dec 2027 expected colorectal cancer Sun Yat-sen University Recruiting No outcome recorded
Phase 2 NCT07393555 Aug 2026 → Nov 2028 expected non-small cell lung carcinoma SWOG Cancer Research Network Not yet recruiting No outcome recorded
Phase 2 NCT07712094 Aug 2026 → Feb 2029 expected neuroendocrine neoplasm Tianjin Medical University Cancer Institute and Hospital Not yet recruiting No outcome recorded
Phase 2 NCT07064902 Aug 2026 overdue nasopharyngeal carcinoma Sun Yat-sen University Not yet recruiting No outcome recorded
Phase 2 NCT07650838 Aug 2026 → Dec 2027 expected soft tissue sarcoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT07815665 Sep 2026 → Oct 2030 expected urothelial carcinoma Summit Therapeutics Recruiting No outcome recorded
Phase 315 trials · 3 met primary
Phase 3 NCT07264075 May 2026 → May 2030 expected head and neck squamous cell carcinoma Groupe Oncologie Radiotherapie Tete et Cou Recruiting No outcome recorded
Phase 3 NCT07228832 Nov 2025 → May 2028 expected colorectal cancer Summit Therapeutics Recruiting No outcome recorded
Phase 3 NCT06928389 Jul 2025 → May 2027 expected non-small cell lung carcinoma Akeso Recruiting No outcome recorded
Phase 3 NCT07010263 Jun 2025 → Dec 2028 expected small cell lung carcinoma Akeso Recruiting No outcome recorded
Phase 3 NCT06953999 Jun 2025 → May 2027 expected malignant pancreatic neoplasm Akeso Recruiting No outcome recorded
Phase 3 NCT06951503 May 2025 → Jan 2027 expected colorectal adenocarcinoma Akeso Recruiting No outcome recorded
Phase 3 NCT06767514 Feb 2025 → Apr 2028 expected non-small cell lung carcinoma Summit Therapeutics Recruiting No outcome recorded
Phase 3 NCT06767527 Feb 2025 → Dec 2026 expected triple-negative breast carcinoma Akeso Recruiting No outcome recorded
Phase 3 NCT06601335 Oct 2024 → Jan 2027 expected head and neck squamous cell carcinoma Akeso Recruiting No outcome recorded
Phase 3 NCT06591520 Oct 2024 → Oct 2026 expected biliary tract cancer Akeso Active not recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT06930573 Dec 2024 → May 2026 overdue hepatocellular carcinoma The First Affiliated Hospital of Zhengzhou University Recruiting No outcome recorded
Phase not applicable2 trials
— NCT06936488 Mar 2025 → Oct 2026 expected colorectal adenocarcinoma Huai'an First People's Hospital Enrolling by invitation No outcome recorded
— NCT06766591 Jan → Oct 2025 overdue neoplastic meningitis, non-small cell lung carcinoma Jiangsu Province Nanjing Brain Hospital Not yet recruiting No outcome recorded
Comparator or background therapy7 trials
Phase 1 NCT07614646 Background Nov 2026 → Jul 2028 expected non-small cell squamous lung carcinoma Everest Medicines (Beijing) Co., Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT07857135 Comparator Oct 2026 → Feb 2029 expected — CSPC Megalith Biopharmaceutical Co.,Ltd. Not yet recruiting No outcome recorded
Phase 1/2 NCT06877650 Background Apr 2025 → Mar 2028 expected cancer Shanghai JMT-Bio Inc. Recruiting No outcome recorded
Phase 2 NCT07234877 Background Nov 2026 → Jan 2032 expected non-small cell lung carcinoma European Organisation for Research and Treatment of Cancer - EORTC Not yet recruiting No outcome recorded
Phase 2 NCT07245446 Background Oct 2025 → Dec 2027 expected small cell lung carcinoma Akeso Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 56

DateIssuerRelease
2026-09-22 Akeso Results 依沃西1L胆道癌III期OS数据入选LBA，康方生物近30项研究闪耀ESMO 2026！ akesobio.com ↗
其中，依沃西联合化疗对比度伐利尤联合化疗一线治疗晚期胆管癌Ⅲ期的OS阳性数据(HARMONi-GI1)入选主席论坛，将以LBA形式重磅口头报告；
2026-09-15 Akeso Results 口头报告|依沃西对比帕博利珠单抗一线治疗PD-L1阳性NSCLC的OS统计学显著阳性结果在WCLC 2026重磅发布（HARMONi-2研究） akesobio.com ↗
研究结果显示：较帕博利珠单抗，依沃西一线治疗PD-L1阳性晚期NSCLC显著延长患者总生存期（OS），达到预设统计学显著性并具有明确临床获益；预设亚组分析总体上呈现一致的OS获益趋势，其中PD-L1高表达人群尤为突出.
2026-09-03 Akeso Results 对比帕博利珠单抗获OS显著阳性结果！依沃西HARMONi-2研究期中分析达到OS关键次要终点，一线治疗PD-L1表达阳性NSCLC akesobio.com ↗
经独立数据监察委员会(IDMC)评估的预先设定的总生存期(OS)期中分析显示：研究达到总生存期(OS)关键次要终点，取得具有统计学显著性和临床获益的阳性结果.
2026-08-26 Akeso Results 对比国际金标准取得OS显著阳性结果！依沃西联合化疗一线治疗胆道癌III期达到主要终点 akesobio.com ↗
研究达到总生存期(OS)主要研究终点，取得具有统计学显著性和重大临床获益的阳性结果；研究也达到无进展生存期(PFS)与客观缓解率(ORR)的所有关键次要终点.
2026-08-18 Akeso Results 荣登Nature Medicine！依沃西联合化疗一线治疗TNBC II期研究结果发表，III期注册性研究高效推进 akesobio.com ↗
近日，康方生物全球首创的肿瘤免疫2.0基石药物依达方®（通用名：依沃西单抗注射液）联合化疗，用于一线治疗局部晚期不可切除或转移性三阴性乳腺癌(TNBC)的II期临床研究结果，全文发表于国际顶级医学期刊《自然·医学》(Nature Medicine).
2026-08-12 Akeso Regulatory 依沃西联合化疗治疗一线sq-NSCLC重磅获批上市，HARMONi-6重塑肺癌治疗金标准 akesobio.com ↗
2026年8月12日，康方生物（9926.HK）欣喜宣布，公司全球首创的肿瘤免疫2.0基石药物依达方®（通用名：依沃西单抗注射液）联合化疗一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)的新药上市申请（sNDA），已获得国家药品监督管理局(NMPA)批准上市.
2026-07-29 Shanghai Allink Biotherapeutics Co., Ltd. Regulatory Allink Biotherapeutics and Akeso Announce Clinical Collaboration to Evaluate FGFR2b ADC Plus Ivonescimab for Squamous Cell Lung Cancer allinkbio.com ↗
The IND application for this combination study was recently approved by the NMPA in China.
2026-06-09 Akeso Results 四靶点协同抗肿瘤！康方首创TIGIT/TGF-β双靶点抗体融合蛋白联合依沃西后线治疗胆道癌优异数据发布|ASCO2026 akesobio.com ↗
45mg/kg Q3W（推荐的II期研究剂量，RP2D）组ORR为25.0%，DCR为68.8%；且获得疾病控制的患者中，85.7%观察到肿瘤明显退缩；
2026-05-31 Akeso Results OS显著阳性，HR=0.66！依沃西联合化疗战胜PD-1联合化疗OS结果在ASCO盛大发布，一线治疗sq-NSCLC akesobio.com ↗
研究结果显示，相比替雷利珠单抗联合化疗，依沃西联合化疗可显著延长患者OS.
2026-04-08 Akeso Results 强效脑保护！依沃西实现NSCLC脑转移“治疗+预防”双重获益|2026ELCC akesobio.com ↗
本次ELCC公布的结果显示，无论基线是否存在脑转移，联合依沃西均可带来更长的颅内PFS获益，且颅内脑转移累积发生率更低.
2026-02-06 Akeso Regulatory 依沃西获得第五个突破性疗法认定，一线治疗胆道癌！ akesobio.com ↗
近日，据国家药品监督管理局药品审评中心（CDE）官网公示结果，康方生物自主研发的全球首创双特异性抗体新药依沃西（PD-1/VEGF双抗）联合疗法用于一线治疗晚期胆道恶性肿瘤（BTC）已被纳入突破性治疗药物（BTD）名单.
2025-12-11 Akeso Results 长期随访疗效突破性愈发凸显！依沃西方案一线治疗TNBC优异更新数据在ESMO IO 2025发布 akesobio.com ↗

All press releases naming this drug 63 releases

DateIssuerRelease

Evidence & citations 10 cited values

Every value below carries the sentence it was read from. 173 sources stand behind the page.

FieldValueCited text
Known as ivonescimab “As the world's first PD-1/VEGF bispecific antibody, ivonescimab ((AK112) has shown superior systemic efficacy compared to conventional VEGF targeted therapy combined with...” NCT06809517 ↗
117

“This is an open-label, single arm , Ib/II phase trial to evaluate the efficacy and safety of AK112（ivonescimab）monotherapy as first-line treatment for favourable risk...” NCT06472895 ↗

“A Prospective, Parallel, Double-cohort, Multicenter Phase II Clinical Study of Ivonescimab (AK112) Combined With IP Chemotherapy ± TACE for First-line Treatment of Metastatic...” NCT07712094 ↗

“A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or...” PMID 37879536 ↗ Oct 2023

“A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined with Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for Resectable, Locally Advanced...” NCT07385001 ↗

“The advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation will receive the combination of fulzerasib (IBI351) with ivonescimab (AK-112) in...” NCT06936644 ↗

“Patients with squamous cell carcinoma received docetaxel administered in 3-week cycles, and patients with adenocarcinoma received pemetrexed, patinum and one of sintilimab or...” NCT07076693 ↗

“Ivonescimab (AK112) is a first-in-class bispecific antibody that simultaneously targets programmed death-1 (PD-1) and vascular endothelial growth factor (VEGF) with cooperative binding.” PMID 40114411 ↗ Mar 2025

“The immunotherapy drug used is Ivonescimab (AK112) (20mg/kg) , administered every 3 weeks concurrently with chemotherapy for 8 cycles.” NCT06402435 ↗

“Ivonescimab is a humanized IgG1 bispecific anti-programmed cell death protein 1/vascular endothelial growth factor antibody.” PMID 39490738 ↗ Oct 2024

“Ivonescimab is a novel humanized tetrameric IgG-scFv bispecific antibody targeting PD-1 and VEGF.” NCT07130240 ↗

Show 107 more sources
Known as AK112 “A Prospective, Single Arm, Open Label, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab (AK112) Combined With TAS-102 in the Treatment of Refractory MSS/pMMR...” NCT06936488 ↗
76

“The advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutation will receive the combination of fulzerasib (IBI351) with ivonescimab (AK-112) in...” NCT06936644 ↗

“All enrolled subjects will receive Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W) in combination with HAIC (utilizing the FOLFOX chemotherapy regimen)” NCT06375486 ↗

“Ivonescimab (AK112) is a novel PD-1/VEGF bispecific antibody designed to simultaneously block PD-1-mediated immune evasion and inhibit VEGF-driven angiogenesis.” NCT07064902 ↗

“Ivonescimab (AK112/SMT112) is a bispecific antibody targeting PD-1 and VEGF, designed to simultaneously modulate immune and angiogenic pathways.” NCT07158489 ↗

“This study was designed to evaluate the efficacy and safety of YL201 in combination with Ivonescimab (AK112) in subjects with solid tumor.” NCT07208773 ↗

“Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles.” NCT05184712 ↗

“Ivonescimab(AK112) combined with chemotherapy in the treatment of advanced esophageal squamous cell carcinoma (ESCC).” NCT06489197 ↗

“Trastuzumab Rezetecan (SHR-A1811) combined with ivonescimab (AK112)” NCT07630077 ↗

“Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W)” NCT06944106 ↗

“Ivonescimab (AK112) + platinum-based doublet chemotherapy” NCT07086326 ↗

Show 66 more sources
Known as Envafolimab “combined with AK112 (Envafolimab) with or without chemotherapy” NCT06718543 ↗
Known as Ivonescimab Injection “Drug: Ivonescimab Injection” NCT07228832 ↗
Known as ivosidan “The purpose of this study is to evaluate the safety and efficacy of AMT-116 in combination with ivosidan (AK112) in patients with advanced non-small cell lung cancer (NSCLC).” NCT07590531 ↗
Known as Ivosimab “An Open-label, Multicenter Phase Ib/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMT116 in Combination With Ivosimab (AK112) in Patients With...” NCT07590531 ↗
Known as SMT112 “Ivonescimab (AK112/SMT112) is a bispecific antibody targeting PD-1 and VEGF, designed to simultaneously modulate immune and angiogenic pathways.” NCT07158489 ↗
5

“Subjects will receive Ivonescimab (SMT112 or AK112) Plus Pemetrexed and Carboplatin via intravenous infusion (IV) Q3W, up to 4 cycles.” NCT05184712 ↗

“Ivonescimab (SMT112 /AK112) Plus Pemetrexed and Carboplatin” NCT06396065 ↗

“Ivonescimab (SMT112 or AK112) Injection” NCT06913218 ↗

“Ivonescimab (SMT112 or AK112) Injection” NCT06760520 ↗

“ivonescimab (AK112/SMT112)” PMID 38642937 ↗ Apr 2024
Action Inhibit “Serum VEGF level was rapidly down-regulated after each administration.” PMID 40114411 ↗ Mar 2025
Modality Monoclonal antibody “humanized IgG1 bispecific antibody” PMID 37593227 ↗ Aug 2023
Route Intravenous “20 mg/kg IV Q3W monotherapy” NCT01042379 ↗